Lung cancer is still the most common cause of death from cancer, both in men and women. Some optimism can be gained from the fact that the lung cancer death rate in men peaked in 1984, and has slowly declined since. This decline appears mostly related to the decreasing use of cigarettes in men in the 1960s and 1970s rather than improvements in diagnosis or therapy. In women the lung cancer death rate has continued to increase although it may have recently reached a plateau.
Functional imaging with PET and PET/CT continues to play an important role in the staging and treatment of lung cancer patients. It can determine the extent of the disease at initial diagnosis. PET is more accurate than CT in determining tumor stage and provides a cost-effective tool for differentiating operable from inoperable disease. In addition, it is effective in ascertaining lung tumor response to therapy and in detecting recurrence in successfully treated lesions.
Contemporary Memoir
by Kerry Grinkmeyer
New research from Boston and Germany this month suggests that adding respiratory gating to a standard whole-body PET/CT scan delivers superior data in the form of more accurate tumor volume measurements and standardized uptake values (SUVs). This data is critical for monitoring therapy response and assessing tumor viability. In addition, it can deliver better patient care in treatment planning before radiation therapy as irradiation target volumes can be more precisely defined.
From Japan comes promising news of a new amino-acid tracer for PET imaging, fluoro methyl tyrosine (FMT). Researchers at Gunma University Graduate School of Medicine have found that PET imaging with the compound seems to deliver a stronger prognostic factory for pulmonary adenocarcinoma than does FDG-PET imaging.
In other news, if you want to find out more about the possibilities for molecular imaging in your practice head over to our Healthcare TechGuide and check out the variety of systems offered there.
Lastly, if you have a comment or report to share about the utilization of molecular imaging and nuclear medicine in your practice, please contact me at the address below. I look forward to hearing from you.
Jonathan Batchelor, Editor
jbatchelor@trimedmedia.com
PET Scans
